I agree Suzuki. They are definitely worried in my opinion of the competition risk posed by Oncosil. They have a vested interest in casting doubt and talking the stock down. As to the sample size they keep banging on about, that was set by BSI. BSI asked for supplementary data for 20 patients. Oncosil delivered 42 patient data. Double what was asked by BSI. So, what they are talking about is completely false and misleading as it applies to Oncosil.
CE Mark Odds, page-126
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.78M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.7¢ | 0.6¢ | $116.5K | 16.65M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 12312335 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3137908 | 9 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |